moneyheap
PFE · Analysis updated Nov 6, 2026, 6:04 PM ET
Why is Pfizer Inc. (PFE) stock moving?
Pfizer continues to trade around the $29.88–$30.00 region after touching an intraday 52-week peak of $31.44 on heavy turnover of 53.1M shares following its Q3 2026 earnings beat. The pharmaceutical giant lifted full-year 2026 revenue guidance to $62.0B–$64.0B and adjusted diluted EPS to $2.95–$3.05, underpinned by 7% non-COVID operational growth and a 32% operational jump in acquired and launched therapies like Padcev ($720M) and Eliquis ($2.52B). Although COVID product revenues dropped to $1.26B and short-term profit taking emerged at the $31 mark, Pfizer's execution on its $7.2B net cost savings program, robust oncology pipeline, and high dividend yield provide stable fundamental support.
News behind the analysis
- Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 GuidancePfizer reported Q3 2026 revenue of $16.6B with adjusted EPS of $0.87, raising full-year revenue guidance to $62.0B–$64.0B and adjusted EPS to $2.95–$3.05.
- Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 resultsStrong demand for cancer therapy Padcev and blood thinner Eliquis fueled a quarterly earnings beat and full-year guidance upgrade.
- Pfizer Reports Earnings: Shares Near Multi-Year HighsPfizer beat consensus with non-COVID product operational revenue expanding 7%, while new CFO Cecile Guegan officially assumed leadership.
- Pfizer Lifts 2026 Revenue Guidance as Non-COVID Sales Grow 7%Launched and acquired products surged 32% operationally to $3.8B, offsetting COVID-19 franchise contraction as the firm delivered on cost reduction targets.
- Pfizer Q3 2026 Results Product Performance: Eliquis, Padcev and Vyndaqel Lead GrowthPadcev surged 55% to $720M and Eliquis advanced 25% to $2.52B, absorbing a $0.10 per-share licensing charge from the Innovent transaction.